A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients
Study sponsor: Vera Therapeutics, Inc. · VERA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2022-02-10Actual
Enrollment · participants30Actual
Source updated2023-06-07Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.